Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

Next Previous
X
Search
Trial Profile

A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varoglutamstat (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms VIVA-MIND
  • Sponsors Vivoryon Therapeutics

    • Most Recent Events

    • 21 Aug 2024 Status changed from active, no longer recruiting to discontinued.
    • 03 Jul 2024 Status changed from recruiting to active, no longer recruiting.
    • 23 May 2024 According to a Vivoryon Therapeutics media release, research and development expenses increased by EUR 4.3 million, which was largely attributable to the increase in clinical development costs from the VIVIAD and VIVA-MIND studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top